Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms

Urologia Internationalis

Volumn 58, Issue 4, 1997, Pages 199-202

  Yaman, Önder ^a   Özdiler, Erol ^a   Orhan, Diclehan ^a   Sak, Serpil Dizbay ^a   Baltacı, Sümer ^a   Tulunay, Özden ^a   GÖğüş, Orhan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Immunohistochemistry; p53; Prostate carcinoma; Tumor suppressor gene

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0030808886     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282983     Document Type: Article

References (19)

1. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991;351:453-456.
2. Dinjens WN, Van Der Weiden MM, Schroeder FH, Bosnian FT, Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994;56:630-633.
3. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85:1657-1669.
4. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C: Immunohistochemi-cal determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-1280.
5. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austcnfcld MS, Stephans RL: Mutant p53 expression in prostate carcinoma. Prostate 1993; 22:23-30.
6. Whitmore WF Jr, Catolona WJ, Brayhack JT, Hanks C, Peters PC, Shipley WU, Walsh PC: Organ systems program staging classification for prostate cancer; in Coffex DS, Resniek MI. Dorr FA. Karr JP (eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. New York, Plenum, 1988, pp 295-297.
7. Gleason DF: Histologic grading of prostatic carcinoma 83-95: in Bostwick DG (ed): Pathology of the Prostate. New York. Churchill Livingstone. 1990.
8. Varley JM, Brammer WJ, Lane DP. Swallow JE. Dolan D. Walker RA: Loss of chromosome 17p 13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991:6: 413-415.
9. Baker SJ, Fcaron HR, Nigro JM. Hamilton SR, Preisinger AC, Jessup JM, Van Tuinen P, Ledbetter DH, Barker DF. Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 1989:244:217-230.
10. Mori N, Yokota J, Oshimura M, Cavenee WK, Mizoguchi H, Noguchi M, Shimosato Y, Sugirnura T, Terada M: Concordant deletions of chromosomes 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. Cancer Res 1989;49:5130-5134.
11. Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E, Kameya T, Koshiba K: p53 mutations and prognosis in bladder tumors. J Urol 1995:153:1097-1104.
12. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716.
13. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-887.
14. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DG: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993.53:3369-3373.
15. Meyers RB, Oelschlager D, Srivastava S, Grizzle WE: Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic. Prostate 1994;25:243-248.
16. Carbone DP, Minna JD: Antioncogenes and human cancer. Annu Rev Med 1993:44:451-464.
17. Cordon-Cardo C, Iatres E, Dronbrijak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ: Molecular abnormalities of mdnt2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799.
18. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? Revisited. J Pathol 1994:172:1-4.
19. Hall MC, Navonc NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LWK: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-475.